Hutchmed Limited Stock Net Asset
| HMDCF Stock | USD 3.02 0.00 0.00% |
As of the 7th of February, HUTCHMED (China) retains the risk adjusted performance of (0.13), and Market Risk Adjusted Performance of (1.13). HUTCHMED (China) technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out HUTCHMED Limited coefficient of variation, as well as the relationship between the total risk alpha and skewness to decide if HUTCHMED (China) is priced adequately, providing market reflects its last-minute price of 3.02 per share. Given that HUTCHMED Limited has variance of 2.9, we strongly advise you to confirm HUTCHMED Limited's regular market performance to make sure the company can sustain itself next year.
HUTCHMED (China)'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing HUTCHMED (China)'s valuation are provided below:HUTCHMED Limited does not currently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. HUTCHMED |
HUTCHMED (China) 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to HUTCHMED (China)'s pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of HUTCHMED (China).
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in HUTCHMED (China) on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding HUTCHMED Limited or generate 0.0% return on investment in HUTCHMED (China) over 90 days. HUTCHMED (China) is related to or competes with Aspen Pharmacare, Sihuan Pharmaceutical, Curaleaf Holdings, Hypera SA, Dermapharm Holding, and Haw ParLtd. HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immuno... More
HUTCHMED (China) Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure HUTCHMED (China)'s pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess HUTCHMED Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 12.84 |
HUTCHMED (China) Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for HUTCHMED (China)'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as HUTCHMED (China)'s standard deviation. In reality, there are many statistical measures that can use HUTCHMED (China) historical prices to predict the future HUTCHMED (China)'s volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (1.14) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HUTCHMED (China)'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
HUTCHMED (China) February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (1.13) | |||
| Mean Deviation | 0.5339 | |||
| Coefficient Of Variation | (618.22) | |||
| Standard Deviation | 1.7 | |||
| Variance | 2.9 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.31) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (1.14) | |||
| Maximum Drawdown | 12.84 | |||
| Skewness | (6.80) | |||
| Kurtosis | 48.3 |
HUTCHMED Limited Backtested Returns
HUTCHMED Limited holds Efficiency (Sharpe) Ratio of -0.17, which attests that the entity had a -0.17 % return per unit of volatility over the last 3 months. HUTCHMED Limited exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out HUTCHMED (China)'s market risk adjusted performance of (1.13), and Risk Adjusted Performance of (0.13) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.25, which attests to not very significant fluctuations relative to the market. As returns on the market increase, HUTCHMED (China)'s returns are expected to increase less than the market. However, during the bear market, the loss of holding HUTCHMED (China) is expected to be smaller as well. At this point, HUTCHMED Limited has a negative expected return of -0.29%. Please make sure to check out HUTCHMED (China)'s information ratio, and the relationship between the coefficient of variation and skewness , to decide if HUTCHMED Limited performance from the past will be repeated at some future point.
Auto-correlation | 0.00 |
No correlation between past and present
HUTCHMED Limited has no correlation between past and present. Overlapping area represents the amount of predictability between HUTCHMED (China) time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of HUTCHMED Limited price movement. The serial correlation of 0.0 indicates that just 0.0% of current HUTCHMED (China) price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, HUTCHMED Limited has a Net Asset of 1.37 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.
HUTCHMED Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HUTCHMED (China)'s direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of HUTCHMED (China) could also be used in its relative valuation, which is a method of valuing HUTCHMED (China) by comparing valuation metrics of similar companies.HUTCHMED is currently under evaluation in net asset category among its peers.
HUTCHMED Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.64) % | |||
| Operating Margin | (0.95) % | |||
| Current Valuation | 1.66 B | |||
| Shares Outstanding | 864.77 M | |||
| Shares Owned By Insiders | 44.52 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 6.53 X | |||
| Revenue | 356.13 M | |||
| Gross Profit | (201.19 M) | |||
| EBITDA | (207.96 M) | |||
| Net Income | (194.65 M) | |||
| Cash And Equivalents | 829.71 M | |||
| Cash Per Share | 0.98 X | |||
| Current Ratio | 3.18 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (204.22 M) | |||
| Number Of Employees | 2.11 K | |||
| Beta | 0.9 | |||
| Market Capitalization | 3.24 B | |||
| Total Asset | 1.37 B | |||
| Net Asset | 1.37 B |
About HUTCHMED (China) Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HUTCHMED Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HUTCHMED (China) using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HUTCHMED Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in HUTCHMED Pink Sheet
HUTCHMED (China) financial ratios help investors to determine whether HUTCHMED Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED (China) security.